禾元生物-U
(688765)
| 流通市值：31.55亿 | | | 总市值：275.28亿 |
| 流通股本：4097.88万 | | | 总股本：3.58亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 19,660,778.26 | 12,710,455.19 | 4,143,100 | 25,216,117.36 |
| 营业收入 | 19,660,778.26 | 12,710,455.19 | - | 25,216,117.36 |
| 二、营业总成本 | 152,128,298.94 | 104,059,673.66 | - | 194,140,323.14 |
| 营业成本 | 9,813,487.42 | 5,263,245.8 | - | 9,206,750.25 |
| 税金及附加 | 1,879,010.79 | 1,262,950.56 | - | 1,920,162.7 |
| 销售费用 | 4,847,569.76 | 2,695,026.46 | - | 4,467,215.28 |
| 管理费用 | 59,050,871.71 | 36,646,653.59 | - | 58,883,455.41 |
| 研发费用 | 72,533,776.31 | 55,936,535.09 | - | 116,786,228.31 |
| 财务费用 | 4,003,582.95 | 2,255,262.16 | - | 2,876,511.19 |
| 其中:利息费用 | 5,663,263.43 | 3,739,831.76 | - | 5,095,929.44 |
| 其中:利息收入 | 1,713,038.3 | 1,542,038.44 | - | 2,403,896.27 |
| 三、其他经营收益 | | | | |
| 资产处置收益 | 3,189,411.24 | 2,463,090.15 | - | -1,277,651.54 |
| 资产减值损失(新) | -692,022.84 | -368,217.96 | - | -477,417.72 |
| 信用减值损失(新) | -38,621.66 | -354,937.62 | - | -3,422.2 |
| 其他收益 | 8,737,849.76 | 7,981,468.06 | - | 19,314,578.01 |
| 营业利润平衡项目 | 0 | 0 | - | 0 |
| 四、营业利润 | -121,270,904.18 | -81,627,815.84 | - | -151,368,119.23 |
| 利润总额平衡项目 | 0 | 0 | - | 0 |
| 五、利润总额 | -121,270,904.18 | -81,627,815.84 | -48,195,200 | -151,368,119.23 |
| 六、净利润 | -121,270,904.18 | -81,627,815.84 | - | -151,368,119.23 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -121,270,904.18 | -81,627,815.84 | - | -151,368,119.23 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -121,270,904.18 | -81,627,815.84 | -48,195,200 | -151,368,119.23 |
| 扣除非经常损益后的净利润 | -131,445,104.18 | -90,535,300.05 | -48,808,700 | -166,747,441.91 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.45 | -0.3 | - | -0.56 |
| (二)稀释每股收益 | -0.45 | -0.3 | - | -0.56 |
| 九、综合收益总额 | -121,270,904.18 | -81,627,815.84 | - | -151,368,119.23 |
| 归属于母公司股东的综合收益总额 | -121,270,904.18 | -81,627,815.84 | - | -151,368,119.23 |
| 公告日期 | 2025-10-24 | 2025-09-23 | 2025-06-24 | 2025-03-31 |
| 审计意见(境内) | | 标准无保留意见 | | 标准无保留意见 |